Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens.
The development of potent adjuvants, conditioning innate and adaptative immunity, particularly CTL responses, has become currently a hot point in the rational design of vaccines for cancer immunotherapy. We have described a new approach, in which gangliosides are incorporated into vesicles from Neisseria meningitidis to form Very Small Size Proteoliposomes (VSSP). VSSP is a good alternative to the existing adjuvants for use in whole cells vaccines since it promotes 80% tumour rejection and growing delay in the CT26 and F3II tumour models respectively. Also VSSP induces activation of CTL responses to co-injected trimmed peptides and soluble proteins. This phenomena is facilitated by the cross-presentation of exogenous antigen and do not need cooperation of CD4 T cells for primary CD8 T cells expansion.
Mesa
Circe
C
Vaccine's Department, Centre of Molecular Immunology, 216 esq 15, Atabey, Playa, CP 16040, C. Habana, Cuba. circe@ict.cim.sld.cu
de León
Joel
J
Fernández
Luis E
LE
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000277:Adjuvants, Pharmaceutic; D000818:Animals; D000917:Antibody Formation; D000942:Antigens, Bacterial / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009345:Neisseria meningitidis / Q000737:chemistry*; D010455:Peptides / Q000276:immunology; D011510:Proteolipids / Q000008:administration & dosage* / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D000277:Adjuvants, Pharmaceutic; D000942:Antigens, Bacterial; D010455:Peptides; D011510:Proteolipids; D022223:Vaccines, Subunit; C020485:proteoliposomes